Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

GlobeNewswire October 19, 2020

Registration Is Now Open For Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

GlobeNewswire October 7, 2020

Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family

PR Newswire October 2, 2020

Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

GlobeNewswire September 21, 2020

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

GlobeNewswire September 17, 2020

Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to Survive Coronavirus" Reaches #1 on Five Amazon Bestsellers Lists

PR Newswire September 14, 2020

Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus

PR Newswire September 8, 2020

Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

GlobeNewswire September 1, 2020

LD Micro - 360 Companies Set to Present this Week

Accesswire August 31, 2020

Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

GlobeNewswire August 26, 2020

Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

GlobeNewswire August 17, 2020

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19

GlobeNewswire August 3, 2020

Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

GlobeNewswire July 30, 2020

Registration Is Now Open for Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event on July 30, 2020

GlobeNewswire July 27, 2020

Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa's Second COVID-19 Therapeutic Development Program

GlobeNewswire July 16, 2020

Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

GlobeNewswire July 15, 2020

Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls

GlobeNewswire July 8, 2020

Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201

GlobeNewswire June 11, 2020